Legend Biotech Corporation vs Pfizer, Inc. — Stock Comparison
Legend Biotech Corporation (LEGN) and Pfizer, Inc. (PFE) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Legend Biotech Corporation narrowly edges Pfizer, Inc. on Q·Score (6.4 vs 5.9 out of 10), led by Valuation (9.1 vs 6.2) and Sentiment (6.9 vs 5.2). Pfizer, Inc. scores higher on Quality, reflecting stronger profitability and returns. Analyst consensus targets imply greater upside for LEGN (+174.4%) than for PFE (+4.8%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Consensus analyst target of $48.48 is 174% above current price.
⚠ currently unprofitable (-7% margin).
Consistently beats earnings estimates (4/4 quarters).
⚠ weak profitability metrics drag quality score.
Analyst Consensus
Fundamentals
Frequently Asked Questions
LEGN vs PFE: which stock scores better overall?
Based on Q·Score, Legend Biotech Corporation (LEGN) scores 6.4/10 versus Pfizer, Inc. (PFE) at 5.9/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: LEGN or PFE?
Pfizer, Inc. (PFE) scores higher on Growth (5.9/10 vs 5.8/10). Legend Biotech Corporation reports revenue growth (51.9% YoY) while Pfizer, Inc. reports (2.6% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is LEGN or PFE more attractively valued?
Legend Biotech Corporation (LEGN) scores higher on Valuation (9.1/10 vs 6.2/10). LEGN trades at 16.8× P/E versus PFE at 9.5×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about LEGN vs PFE?
There are 14 analysts covering LEGN with a consensus price target of $48.48, and 26 analysts covering PFE with a consensus target of $28.88. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: LEGN or PFE?
Pfizer, Inc. (PFE) scores higher on Quality (5/10 vs 2.8/10). Net profit margin: LEGN at -7.2%, PFE at 6.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: LEGN or PFE?
Legend Biotech Corporation (LEGN) scores higher on Financial Health (8.4/10 vs 7/10). Market beta: LEGN at 0.40, PFE at 0.30. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of LEGN and PFE?
Legend Biotech Corporation (LEGN) has a market capitalisation of $3.4B, while Pfizer, Inc. (PFE) has a market cap of $157.0B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do LEGN or PFE pay dividends?
LEGN does not currently pay a dividend, while PFE pays a dividend yield of 6.20%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →